Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06314490

Personalized Antisense Oligonucleotide Therapy for Rare Pediatric Genetic Disease: SCN2A

This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single pediatric participant with SCN2A associated developmental epileptic encephalopathy

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Rady Children's Hospital

San Diego, California, 92123, United States

About this study

This is an interventional study to evaluate the safety and efficacy of treatment with an individualized antisense oligonucleotide (ASO) treatment in a single pediatric participant with a de novo pathogenic gain of function SCN2A mutation associated with severe developmental epileptic encephalopathy.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Informed consent provided by the participant's parent(s)/guardian(s)
  • Ability to travel to the study site, adhere to study-related follow-up examinations and/or procedures, and provide access to participant's medical records.
  • Genetically confirmed mutation

Exclusion criteria

  • Use of an investigational medication within less than 5 half-lives of the drug at enrollment

Treatment and study plan

nL-SCN2A-002

Drug

Personalized antisense oligonucleotide

Primary outcomes

  1. Seizure frequency

    Time frame: Baseline to 24 months

    As measured by caregiver provided seizure diary

  2. Motor function as measured by Dyskinetic Cerebral Palsy Functional Impact Scale

    Time frame: Baseline to 24 months

    The Dyskinetic Cerebral Palsy Functional Impact Scale (D-FIS) is an 18 item caregiver questionnaire that evaluates the impact of dyskinesia on daily functions. It is a validated assessment tool for children aged 2 years and 6 months to 18 years. It uses a 5-point ordinal scale, from 0 (no impact) to 4 (extreme impact), for each item and derives a total score from summing all 18 items. A higher score indicates more severe impact of dyskinesia and worse motor functioning.

  3. Motor function as measured by the motor skills domain of Vineland Adaptive Behavior Scales

    Time frame: Baseline to 24 months

    The Vineland Adaptive Behavior Scales, Third Edition (Vineland-3), is a standardized, validated, and reliable assessment tool designed to measure the adaptive behavior of individuals from birth through adulthood. The Vineland-3 Motor Skills domain evaluates gross and fine motor abilities in individuals from birth to age 9, offering insights into coordination, balance, mobility, and dexterity. The raw scores are converted to standard scores and growth scale value scores, with higher scores indicating better adaptive functioning.

  4. Motor function as measured by the motor skills domain of Bayley Scales of Infant and Toddler Development

    Time frame: Baseline to 24 months

    The Bayley Scales of Infant and Toddler Development is a standardized, validated, and reliable assessment tool for evaluating developmental functioning in infants and toddlers. Its Motor Skills domain evaluates gross and fine motor abilities, including coordination, balance, and movement. The raw scores are converted to standard scores and growth scale value scores, with higher scores indicating better motor development.

  5. Gastrointestinal assessment as measured by the Bristol Stool Chart

    Time frame: Baseline to 24 months

    The Bristol Stool Chart categorizes human feces into seven types, from Type 1 (severe constipation) to Type 7 (diarrhea), with Types 3 and 4 considered normal.

Secondary outcomes

  1. Neurodevelopmental Function as measured by Aberrant Behavior Checklist

    Time frame: Baseline to 24 months

    The Aberrant Behavior Checklist (ABC) is an empirically developed scale tailored to measure psychiatric symptoms and behavioral disturbances in individuals with Intellectual and Developmental Disabilities (IDD). It contains five domains: Irritability, Agitation, & Crying; Lethargy/Social Withdrawal; Stereotypic Behavior; Hyperactivity/Noncompliance; and Inappropriate Speech. Each question is scored on a 4-point scale (0 = not a problem to 3 = severe problem) to assess severity. Total scores per subscale reflect the extent of behavioral challenges, with higher scores indicating greater severity.

  2. Neurodevelopmental Function as measured by Observer-Reported Communication Ability Measure

    Time frame: Baseline to 24 months

    The Observer-Reported Communication Ability (ORCA) Measure is a questionnaire assessing communication abilities in individuals with neurodevelopmental disorders, significantly impacting verbal speech. It includes 84 questions, with 70 behavioral items across 22 concepts/functions and 14 descriptive items about individual communication methods, covering expressive, receptive, and pragmatic communication areas. The ORCA is validated for Angelman and Rett syndromes and is being evaluated for other disorders. The ORCA T-score ranges from 25.8 to 83.8, with higher ORCA T-scores indicate greater communication ability.

  3. Neurodevelopmental Function as measured by the Vineland Adaptive Behavior Scales

    Time frame: Baseline to 24 months

    The Vineland Adaptive Behavior Scales, Third Edition (Vineland-3), is a standardized, validated, and reliable assessment tool designed to measure the adaptive behavior of individuals from birth through adulthood through multiple domains, including communication and socialization. The raw scores are converted to standard scores and growth scale value scores, with higher scores indicating better adaptive functioning.

  4. Neurodevelopmental Function as measured by the Bayley Scales of Infant and Toddler Development

    Time frame: Baseline to 24 months

    The Bayley Scales of Infant and Toddler Development is a standardized, validated, and reliable assessment tool for evaluating developmental functioning in infants and toddlers across subdomains of cognition and language (receptive and expressive communication). The raw scores are converted to standard scores and growth scale value scores, with higher scores indicating better neurodevelopment.

Sponsors and collaborators

Lead sponsor

University of California, San Diego

Other

Collaborators

  • California Institute for Regenerative Medicine (CIRM)
  • n-Lorem Foundation

Registry information

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Mar 18, 2024
Registry last updated
Apr 1, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.